March 31st, 2010 by DrWes in Better Health Network, Opinion, Primary Care Wednesdays, True Stories
No Comments »
It’s very generous of Sanolfi-Aventis’s marketing department to make this offer for me to serve as an “advisor” for dronedarone (Multaq), but seriously–I was a bit skeptical that they wanted my “feedback on the reasons for and against utlilization of Multaq® in the appropriate patient as well as to understand communication and educational needs with regard to Multaq® and the atrial fibrillation state in general.”
Where were they when the drug launched? Might it be because this drug hasn’t quite been the blockbuster they’d hoped for?
But, of course, I’d never be swayed to use more of this drug by such important consulting work. No, really.
P.S. Sanolfi-Aventis marketers: Please update your prescriber database with my correct workplace.
–Musings of a cardiologist and cardiac electrophysiologist.
*This blog post was originally published at Dr. Wes*
March 28th, 2010 by PhilBaumannRN in Better Health Network, Opinion
No Comments »
There’s been an ongoing discussion about how the Life Sciences industries can face and integrate recently-evolving media which the Web has been and continues to sprout. Remarkable as they are, the discussions are endless and most loop back into themselves without generating sufficient voltage to power an army of macrophages. Additionally, pharmaceutical companies (pharma) –- beset by a myriad of constraints –- are anxious about flipping on social connection switches which the Web furiously creates every day. We could say that pharma has a sort of social media anxiety disorder. What to do?
The answer isn’t in social media. It’s not in what the FDA decides to do. It’s not in echo chambers found within Twitter or blogs or conferences. It lies in simple, basic economic truths. It lies in radical acceptance and in brave recreation. It lies beneath the proverbial nose of obviousness. It lies far beyond any discussion about the meanings and promises and purposes of new media on the Web. Pharma’s social media anxiety disorder is merely a peripheral symptom of deeper pathologies. Let’s assess the patient. Read more »
*This blog post was originally published at Phil Baumann*
